Is it safe to initiate bupropion in a patient with cardiovascular disease (e.g., uncontrolled hypertension, recent myocardial infarction, arrhythmia, or structural heart disease), and what dosing and monitoring guidelines should be followed?

Bupropion Use in Cardiovascular Disease

Bupropion can be used cautiously in patients with cardiovascular disease, but it requires careful patient selection, blood pressure and heart rate monitoring, and should be avoided in those with uncontrolled hypertension. The FDA label explicitly warns that bupropion can increase blood pressure, necessitating monitoring before and during treatment 1.

Cardiovascular Safety Profile

Blood Pressure and Heart Rate Effects

• Bupropion increases blood pressure and heart rate, which is the primary cardiovascular concern 1.
• The FDA mandates blood pressure monitoring before initiating treatment and periodically throughout therapy 1.
• In patients with mild untreated hypertension (stage 1), bupropion SR 300 mg/day resulted in less reduction in systolic blood pressure compared to placebo (-4.20 vs -6.53 mm Hg), though the clinical significance was modest 2.
• Heart rate increases were small but statistically significant at 400 mg/day (2.92 beats/min increase vs placebo) 2.

Contraindications and Precautions

Bupropion is contraindicated in patients with uncontrolled hypertension 3, 4. The 2016 AACE/ACE guidelines specifically state that naltrexone ER/bupropion ER should be avoided if other weight-loss medications can be used because weight loss assisted by this combination cannot be expected to reduce blood pressure 4.

For patients with established cardiovascular disease:

• Bupropion is reasonable to use with caution in patients with atherosclerotic cardiovascular disease, provided weight-loss goals are met and careful monitoring of heart rate and blood pressure is maintained 4.
• The 2022 AGA guidelines recommend monitoring blood pressure and heart rate periodically while taking naltrexone-bupropion ER, especially in the first 12 weeks of treatment 5.

Evidence in Acute Cardiac Conditions

Post-Myocardial Infarction Data

The evidence for bupropion safety immediately after myocardial infarction is reassuring but shows limited efficacy for smoking cessation:

• In the ZESCA trial (392 patients with acute MI), bupropion was well-tolerated with similar major adverse cardiac event rates compared to placebo (13.0% vs 11.0%, p=0.64) at 12 months 6.
• A smaller trial of 248 smokers hospitalized with acute cardiovascular disease (primarily MI and unstable angina) showed no difference in cardiovascular mortality at 1 year (0% vs 2%) or cardiovascular events between bupropion and placebo groups 7.
• In stable cardiovascular disease, a multicenter trial of 629 smokers showed no clinically significant changes in blood pressure or heart rate during the 7-week treatment phase 8.

Cardiac Arrhythmias

• Bupropion is not contraindicated in patients with cardiac arrhythmias but should be used cautiously with careful monitoring of heart rate and rhythm 4.
• In depressed patients with preexisting ventricular arrhythmias, bupropion did not exacerbate arrhythmias, though treatment was discontinued in 14% due to adverse effects including hypertension exacerbation 9.
• Recent toxicology data shows that QRS widening (OR 3.01) and QTc prolongation (OR 1.76) are associated with adverse cardiovascular events in bupropion exposures, though these were primarily intentional overdoses 10.

Dosing and Monitoring Guidelines

Initiation and Titration

For depression (bupropion monotherapy):

• Starting dose: 150 mg once daily 1
• After 4 days, may increase to 300 mg once daily 1
• Maximum dose: 450 mg/day 1

For obesity (naltrexone-bupropion ER):

• Week 1: 1 tablet (8 mg naltrexone/90 mg bupropion) once daily in morning 11
• Week 2: 1 tablet twice daily 11
• Week 3: 2 tablets in morning, 1 tablet in evening 11
• Week 4 onward: 2 tablets twice daily (maintenance dose) 11

Monitoring Requirements

Essential monitoring parameters:

• Blood pressure measurement before initiating treatment and periodically during therapy 1
• Heart rate monitoring, especially in the first 12 weeks 5
• For patients on beta-blockers, bupropion may increase beta-blocker levels; consider starting at lower doses and closely monitor heart rate 12

Dose Adjustments for Comorbidities

Renal impairment:

• Moderate to severe renal impairment: Maximum dose of naltrexone-bupropion ER is 1 tablet (8 mg/90 mg) twice daily 11, 12
• Consider reducing dose and/or frequency for any degree of renal impairment 1

Hepatic impairment:

• Moderate to severe hepatic impairment: 150 mg every other day for bupropion monotherapy 1
• For naltrexone-bupropion ER: Maximum 1 tablet (8 mg/90 mg) daily in morning 11, 12
• Not recommended in severe hepatic impairment 12

Clinical Decision Algorithm

Step 1: Assess cardiovascular status

• Uncontrolled hypertension (≥140/90 mmHg)? → Do not initiate bupropion 3, 4
• Recent MI (<3 months) with preserved LVEF? → Can use with caution and close monitoring 6, 7
• Stable cardiovascular disease? → Reasonable to use with monitoring 4, 8

Step 2: Baseline measurements

• Obtain baseline blood pressure and heart rate 1
• Review current cardiac medications, especially beta-blockers 12

Step 3: Initiation with monitoring

• Start at lowest effective dose 1
• Monitor blood pressure and heart rate at 2 weeks, 4 weeks, 8 weeks, and 12 weeks 5
• For naltrexone-bupropion ER, intensify monitoring in first 12 weeks 5

Step 4: Management of blood pressure elevation

• If systolic BP increases >10 mmHg or becomes uncontrolled, consider dose reduction or discontinuation 4
• Optimize antihypertensive therapy before discontinuing bupropion if clinical benefit is significant 4

Common Pitfalls

• Failing to monitor blood pressure regularly: This is an FDA-mandated requirement that is often overlooked in clinical practice 1.
• Using bupropion in uncontrolled hypertension: This is an absolute contraindication that must be respected 3, 4.
• Ignoring drug interactions with beta-blockers: Bupropion inhibits CYP2D6 and can increase metoprolol levels, requiring dose adjustments 1.
• Assuming all cardiovascular disease is a contraindication: Stable cardiovascular disease is not a contraindication; the drug can be used with appropriate monitoring 4, 8.